Business
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held from April 8-13, 2022 in New Orleans, LA. Details of the poster presentations are as follows: Title: Ex-vivo inhibition of CBL-B with a novel small molecule inhibitor, NX-0255, enhances persistence and anti-tumor activity of adoptively transferred CD8+ T cells in mouse tumor modelsAbstract: 573Presenter: Marilena Gallotta, Ph.D.Date and Time: Sunday Apr 10, 2022 1:30 PM - 5:00 PM.Session Title: Adoptive Cell Therapy 2Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37 NX-0255 is an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B) designed to enhance the function of ex vivo expanded T cells for adoptive cell transfer. Data presented at the AACR meeting will include analysis of the effect of in vitro pre-treatment of CD8+ T cells with NX-0255 alone, IL-2 alone, or NX-0255 combined with IL-2 on expansion, cellular phenotype, and the subsequent effect on the treated cells’ ability to reject tumors following adoptive transfer in vivo into established models of lymphoma and melanoma. Nurix has an open Phase 1 clinical trial to evaluate NX-0255-treated TILs (DeTIL-0255) in adults with gynecological malignancies. Nurix anticipates dosing the first patient in the first half of 2022 and providing a clinical update from the run-in portion of the study in the second half of 2022. Additional information on the clinical trial can be accessed at www.clinicaltrials.gov (NCT05107739). Title: Concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killingAbstract: 1126Presenter: Mark A. Noviski, Ph.D.Date and Time: Monday Apr 11, 2022 9:00 AM - 12:30 PMSession Title: Mechanisms of Drug Action 3 Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 24 NX-2127 is a novel bifunctional molecule that degrades Bruton’s tyrosine kinase (BTK) and IMiD neosubstrates. At the AACR meeting data will be presented demonstrating that NX-2127 promotes superior in vitro killing of two d...